Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Dabigatran en het risico op 'Staphylococcus aureus'-bacteriëmie
nov 2021 | Bacteriële infecties, Ritmestoornissen